Mitsubishi Gas Chemical Company, Inc. 4182

Brookfield Asset Management (NYSE:BAM) has agreed to invest up to $600 million in India’s ACME Cleantech Ventures to support the development and construction of green ammonia and green methanol projects, the companies announced on Thursday. The investment marks Brookfield’s entry into the region’s low-carbon fuels sector and will be made through its Brookfield Global Transition Fund strategy.

Why Mitsubishi Gas Chemical Company (TSE:4182) is on investors’ radar today Mitsubishi Gas Chemical Company (TSE:4182) has drawn attention after recent share price moves, with the stock up about 10% over the past 3 months and a year to date return above 70%. See our latest analysis for Mitsubishi Gas Chemical Company. Short term share price momentum has cooled after earlier gains, with the stock roughly flat over the past month but still showing a 19.1% 90 day share price return and strong 1...

GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial for SPD8, a Denosumab biosimilar co-developed with Mitsubishi Gas Chemical, has successfully met its primary endpoint. Statistical analysis confirms that SPD8 demonstrated therapeutic equivalence to the reference drug, Prolia® (marketed as Pralia® in Japan). The company expects to finalize the clinical study report by the end of September, followed by a drug approval application in Japan. Jap

Polyoxymethylene Market Polyoxymethylene Market Dublin, April 15, 2026 (GLOBE NEWSWIRE) -- The "Polyoxymethylene Market by Type, Processing Technique, Grade, End-use Industry, and Region - Global Forecast to 2030" has been added to ResearchAndMarkets.com's offering.The polyoxymethylene market is anticipated to grow from USD 3.73 billion in 2025 to USD 4.64 billion by 2030, with a CAGR of 4.51% during this period. This growth is driven by sustained demand from the automotive, industrial, and elec

GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the last patient has received the final dose in its Phase 3 clinical study of SPD8, a biosimilar to denosumab for the treatment of osteoporosis. Developed in collaboration with Mitsubishi Gas Chemical (MGC), SPD8 is designed to address complications associated with bone metastases in patients with solid tumors and osteoporosis-related conditions. Dosing of the final patient marks a significant milestone for the program,